HER2 expression in GBM cells and the identification of peptide-specific, major histocompatibility complex-limited CTL production in GBM cells lay the foundation for the use of relevant alternative assays to measure antigen-specific cytotoxicity (Liu et al., 2004). Here, ERBB2 is linked to glioblastoma.